A poptosis is a genetically controlled process of programmed cell death, which plays an important role in the development and homeostasis of cells and tissues. [1] [2] [3] Defects in the apoptosis pathway may facilitate the accumulation of somatic mutations, thereby increasing the risk of cancers, including lung cancer. 4, 5 Caspases (CASPs), a family of cysteine-dependent aspartate-specific proteases, are the central engines of apoptosis that orchestrate cell death by cleaving a variety of intracellular substrates that trigger cell dissolution. 5, 6 Based on their proapoptotic functions, CASPs can be categorized into two groups; initiator CASPs and effector CASPs. Extrinsic (CASP8 and CASP10) and intrinsic (CASP9) initiator CASPs transmit death signals and activate effector CASPs (CASP3, CASP6, and CASP7), which execute a coordinated program of proteolysis, resulting in the destruction of critical cell structures. 7, 8 Carcinogenesis is a multistep, multigenic process; therefore, it is unlikely that any single polymorphism would have a dramatic effect on the risk of cancer. A pathway-based multigenic approach, which estimates the combined effects of a set of polymorphisms interacting in the same pathway, may amplify the effects of individual polymorphisms and strengthen the predictive power. 9 -13 We and other investigators have reported that several polymorphisms in CASP genes are associated with risk of diverse types of human cancer. 14 -20 Most of the previous studies analyzed each individual CASP gene and thereby had obvious limitations in revealing possible interactions of multiple CASP genes. In this study, we have added additional genotype data to the existing data of our previous studies 15, 16, 19, 20 and analyzed the joint effects of polymorphisms of multiple CASP genes on the risk of lung cancer.
PATIENTS AND METHODS

Study Population
This case-control study consisted of 720 patients with lung cancer and 720 healthy controls. The details of the study population have been described elsewhere. 15 In brief, eligible cases included all patients newly diagnosed with primary lung cancer between January 2001 and December 2002 at Kyungpook National University Hospital, Daegu, Korea. There were no age, gender, histologic, or stage restrictions, but patients with a history of cancer were excluded from this study. Control subjects were randomly selected from a pool of healthy volunteers restriction fragment length polymorphism who visited the general health checkup center at Kyungpook National University Hospital during the same period. The control subjects were frequency matched (1:1) to the cases based on gender and age (Ϯ5 years). All cases and controls were ethnic Koreans residing in Daegu or the surrounding regions. This study was approved by the Institutional Review Board of the Kyungpook National University Hospital, and written informed consent was obtained from each participant.
Selection of Polymorphisms and Genotyping
In this study, 11 polymorphisms in the CASP3, 6, 7, 8, 9 , and 10 genes were examined in a case-control study. Eight polymorphisms (CASP3 77GϾA and rs2705897; CASP7 rs12415607 and rs2227310; CASP8 rs3834129 and rs3769818; and CASP9 rs4645978 and rs4645981) were selected based on the results of our previous studies. 15, 16, 19, 20 Polymorphisms (rs13010627 and rs13006529) of the CASP10 gene have been reported to be associated with the risk of cutaneous melanoma and familial breast cancer 18, 21 ; however, only rs13006529 was evaluated because rs13010627 is very rare or nonexistent in Asians. For the CASP6 gene, we screened potentially functional variants in the promoter region, all exons including exon-intron boundaries (50 bp on either side of the introns) and the 3ЈUTR using the public database (http://www.ncbi.nlm.nih.gov/SNP) and determined their frequencies in a preliminary study consisting of 27 healthy Koreans and 27 lung cancer cases. Of the four polymorphisms (rs5030516, rs2301717, rs11574697, and rs1042891) captured from the database, rs5030516 and rs11574697 were not detected in the preliminary study population, and thus only the remaining 2 polymorphisms, rs2301717 and rs1042891, were evaluated.
The CASP8 rs3834129 and rs3769818, and CASP9 rs4645978 and rs4645981 genotypes of additional cases and controls were determined using a polymerase chain reaction (PCR)-restriction fragment length polymorphism assay as done in our previous studies. 16, 19 CASP3 77GϾA and rs2705897, CASP6 rs2301717 and rs1042891, CASP7 rs12415607 and rs2227310, and CASP10 rs13006529 genotypes were determined by PCR and melting-curve analysis using fluorescence-labeled hybridization probes (LightCycler 480, Roche Diagnostic, Mannheim, Germany). For quality control, the genotyping analysis was performed blind with respect to the subjects. In addition, approximately 10% of the samples were randomly selected to be genotyped again by a different investigator, and the results were 100% concordant. To confirm the genotyping results, selected PCR-amplified DNA samples (n ϭ 10 for each genotype) were examined by DNA sequencing, and the results were also 100% concordant.
Statistical Analysis
The cases and controls were compared using the Student's t test for continuous variables and a 2 test for categorical variables. Deviations of the genotype frequencies in the controls from those expected under Hardy-Weinberg equilibrium were assessed by 2 test (1 degree of freedom). Unconditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), with adjustment for possible confounding factors (gender as a nominal variable, and age and pack years as continuous variables). For the gene-smoking interaction analyses, we used three approaches to evaluate the consistency of the results: (i) logistic regression model including the interaction term between the genotype and smoking, (ii) stratified analyses in specific categories of cumulative smoking exposure, and (iii) genotype-smoking joint effects. A homogeneity test was conducted to compare the difference between genotype-related ORs of different groups. All statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL).
RESULTS
The demographics of the cases and controls enrolled in this study are shown in Table 1 . There were no significant differences between the cases and controls for mean age or gender distribution, suggesting adequate matching based on these two variables. The case group had a higher prevalence of current smokers than the controls (p Ͻ 0.001), and the number of pack years in smokers was significantly higher in the cases than in the controls (39.8 Ϯ 18.1 versus 32.8 Ϯ 18.0 pack years; p Ͻ 0.001). These differences were controlled in the multivariate analyses.
The distributions of the genotypes of single nucleotide polymorphisms (SNPs) of CASP3, 6, 7, 8, 9 , and 10 among cases and controls are shown in Table 2 . The 
We extended our analysis to investigate the combined effect of SNPs, which were associated with the risk of lung cancer in an individual SNP analysis. The CASP7 rs12415607CϾA was excluded from combined genotype analysis because it was in strong linkage disequilibrium with the rs2227310CϾG. For combined genotype analysis, we considered the CASP3 77 GG, CASP7 rs2227310 GG, and CASP9 rs4645981 CTϩTT genotypes as risk genotypes. The subjects were grouped into four categories based on the number of risk genotypes each subject possessed. As shown in Table 3 , the frequency distribution of the combined genotypes among the cases were significantly different from those among the controls (Global p ϭ 0.002). The risk of lung cancer increased in a dose-dependent manner as the number of risk genotype increased (p trend Ͻ 0.001). Compared with subjects with zero risk genotype, those with two and three risk genotypes carried significantly increased risk (adjusted OR ϭ 1.56, 95% CI ϭ 1.14 -2.13, p ϭ 0.005; adjusted OR ϭ 2.54, 95% CI ϭ 1.28 -5.02, p ϭ 0.008, respectively). When the subjects were dichotomized into two groups, the subjects with at least two risk genotypes were at a 1.5-fold increased risk of lung cancer compared with those with 0 to 1 risk genotype (adjusted OR ϭ 1.51, 95% CI ϭ 1.17-1.96, p ϭ 0.002).
We next explored the combined effect of polymorphisms in the six CASP genes evaluated for the risk of lung cancer. For those genes with multiple polymorphisms assayed, only one polymorphism was included in this combined analysis, and others were excluded because of linkage disequilibrium. The included polymorphisms were CASP3 77GϾA, CASP6 rs2301717, CASP7 rs2227310, CASP8 rs3834129, CASP9 rs4645981, and CASP10 rs13006529. For this analysis, the variant allele at each locus was treated as a risk allele and their combined effect evaluated by grouping the subjects based on the number of risk alleles that each possessed. In the case of the CASP3 77GϾA, the wild-type G allele was treated as a risk allele because the variant A allele was associated with a reduced risk of lung cancer. The number of risk alleles for each individual ranged from 0 to 10. The number of subjects with 0 to 2 and 7 to 10 risk alleles was small, and thus, subjects were divided into four groups as follows: 0 to 3, 4, 5, or 6 to 10 risk alleles. Compared with individuals with 0 to 3 risk alleles, the risk of lung cancer increased as the number of risk alleles increased (p trend ϭ 0.045, Table 3 ). The effect of combined genotypes on lung cancer risk was examined further after stratifying the subjects according to age, smoking status, and tumor histology (Table 4) . Subjects with two to three risk genotypes were compared with those with 0 to 1 risk genotype with respect to the risk of lung cancer. The effect of combined genotype on the risk of lung cancer was significant in younger individuals (adjusted OR ϭ 1.89, 95% CI ϭ 1.28 -2.78, p ϭ 0.001) and ever smokers (adjusted OR ϭ 1.73, 95% CI ϭ 1.28 -2.33, p Ͻ 0.001) but not in older individuals and never smokers. When stratified according to histology, the risk of lung cancer was not different between non-small cell lung cancer and small cell lung cancer.
In addition to the stratification analyses, the joint effect of combined genotypes and smoking on the risk of lung cancer was also investigated to assess a potential genesmoking interaction (Table 5 ). The group of heavy smokers with two or more risk genotypes carried the highest risk of lung cancer compared with the group of never smokers with 0 to 1 risk genotype (adjusted OR ϭ 6.92, 95% CI ϭ 3.95-12.12, p Ͻ 0.001). However, we did not find a significant interaction between combined genotypes and smoking (p ϭ 0.11 for the interaction term).
DISCUSSION
Several studies have found associations between genetic polymorphisms in some CASP genes such as CASP9 and CASP10 and the risk of certain cancers, including lung cancer, and the results are encouraging. 14 -18 However, most of the previous studies were designed to analyze an individual gene, which obviously have limitations to elucidate the effects of entire CASP genes. To comprehensively evaluate the roles of CASP gene polymorphisms in the development of lung cancer, we examined individual and joint effects of 11 potentially functional polymorphisms in six major CASP genes. In this study, three polymorphisms (CASP3 77GϾA, CASP7 rs2227310CϾG, and CASP9 rs4645981CϾT) were associated with the risk of lung cancer. More importantly, the combined analysis of these three polymorphisms showed an increased risk of lung cancer with an increasing number of adverse genotypes. These results were in line with the concept that the estimation of the combined effects of a set of polymorphisms interacting in the same pathway could amplify the effects of individual polymorphisms and have better resolution in risk prediction compared with analysis of each single polymorphism. This is the first study evaluating the effect of combined genotypes of multiple CASP genes on the risk of lung cancer. The most significant finding of this study is that combined analysis of multiple polymorphisms in CASP genes had a much higher potential value in terms of unraveling lung cancer related polymorphisms. Although the CASP3 77 GG, CASP7 rs2227310 GG, and CASP9 rs4645981 CTϩTT genotypes were associated with 1.19-fold, 1.40-fold, and 1.28-fold increased risk of lung cancer in individual polymorphism analysis, respectively, the impact of any individual polymorphism on the risk of lung cancer would be minimal considering the borderline CIs and multiple comparisons. However, when these three polymorphisms were combined, the risk of lung cancer was increased as the number of bad genotypes increased (p trend Ͻ 0.001). The presence of two and three bad genotypes was associated with 1.56-fold and 2.54-fold increased risk compared with subjects with zero risk genotype, respectively. These results indicate that the adverse genotypes of the three polymorphisms additively increase the risk of lung cancer. In addition, this finding indicates that a combined analysis of multiple CASP gene polymorphisms may have a greater power to identify high-risk populations compared with an analysis of a single polymorphism.
Another interesting finding of this study is that the effect of combined genotypes on the risk of lung cancer was modified by smoking. In this study, the presence of two or more risk genotypes was associated with a significantly increased risk of lung cancer only in ever smokers, suggesting that the genotype effect is modified by smoking. In addition, the results of joint effect analysis suggested that the interaction exists between combined CASP genotypes and smoking because the joint effect of two exposures is greater than the product of the individual effects. 22 This interaction was not statistically significant in multivariate logistic regression analysis (p ϭ 0.11 for the interaction term), which is likely due to the limited study power with reduced sample size in the subgroup. Additional studies powered by a greater number of subjects might be needed to confirm the potential genesmoking interaction. 23 Our findings were in agreement with those of previous studies. 15, 16, 20 It was predicted that the CASP3 77 G to A change would create a putative transcription factor binding site to increase the efficiency of CASP3 transcription. 20 Accordingly, the CASP3 77G allele is likely to be associated with an increased risk of lung cancer compared with A allele. In the case of the CASP7 rs2227310CϾG, it is located in the C-terminal end of the CASP7 gene and produces an E to D change in different amino acid positions of non-␤ isoforms and a S244T change in the isoform ␤ of the CASP7. Although the effect of the SNP on protein expression or function remains to be elucidated, it was predicted that the E-to-D change may possibly be damaging the alpha isoform, 15 suggesting that the rs2227310 may be a functional SNP. Alternatively, the association between the rs2227310CϾG and lung cancer may be secondary to linkage disequilibrium with a functional variant in the CASP7 gene, such as the rs2227309GϾA, which produces a K249R change in the ␤ isoform. The CASP9 rs4645981T allele has been reported to be associated with a decreased promoter activity. 16 Therefore, it could be inferred that the CASP9 rs4645981T allele may lead to a lower CASP9 production and decreased apoptotic capacity; and thus, the CASP9 rs4645981 CTϩTT genotype is likely to be associated with an increased lung cancer risk.
These results indicate that the adverse genotypes of the three polymorphisms additively increase the risk of lung cancer. In addition, this finding indicates that a combined analysis of multiple CASP gene polymorphisms may have a greater power to identify high-risk populations compared with analysis of a single polymorphism. Although the combined effect of multiple apoptotic gene polymorphisms on apoptotic capacity has not been studied, the observed gene-dosage effect of CASP gene polymorphisms on the risk of lung cancer may be due to that individual's apoptotic capacity is determined by the collective effect of multiple CASPs. This explanation is supported by several studies that have reported similar dose-dependent relationships between DNA repair gene polymorphisms and DNA repair capacity. 24, 25 Recently, Ulybina et al. 26 investigated the associations of nonsynonymous coding polymorphisms of apoptotic genes, including CASPs with lung cancer in European populations. In their study, three polymorphisms, including the CASP5 rs523104 (V318L) and CASP8 rs1045485 (H302D), showed promising associations in a case-control study consisting of light-or nonsmoking young patients and elderly tumor-free heavy smokers, although these associations did not reach the level of statistical significance in a validation study. In this study, we focused only on major initiator and effector CASP genes (CASP3, 6, and 7, and CASP8-10). CASP8 rs1045485 was not evaluated because it was not detected in a preliminary study of 90 patients with lung cancer and 91 healthy controls as described previously. 19 In conclusion, we demonstrated an additive effect of CASP3 77GϾA, CASP7 rs2227310CϾG and CASP9 rs4645981CϾT on the risk of lung cancer in a Korean population. Additional studies with a larger sample size and in different ethnic groups are required to confirm our findings.
